SWM
CRSP icon

Strategic Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Strategic Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$1.09M Buy
14,360
+7,000
+95% +$612K 0.54% 54
2021
Q3 		$824K Buy
+7,360
New +$924K 0.43% 56

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Strategic Wealth Management's CRSP Position: Q4 2021 in Review

Strategic Wealth Management increased its CRISPR Therapeutics (CRSP) stake by 95% in Q4 2021, buying an estimated $612K and bringing the position to 14,360 shares worth $1.09M. The position accounts for 0.54% of the portfolio, ranked #54.

Strategic Wealth Management first reported a position in CRSP in Q3 2021 and has held it in 2 quarters since. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • Strategic Wealth Management held 14,360 shares of CRISPR Therapeutics worth $1.09M as of Q4 2021.
  • Strategic Wealth Management bought 7,000 CRISPR Therapeutics shares in Q4 2021, an estimated $612K.
  • CRISPR Therapeutics made up 0.54% of Strategic Wealth Management's portfolio in Q4 2021, its #54 holding.
  • Strategic Wealth Management first reported a position in CRISPR Therapeutics in Q3 2021 and has held it in 2 quarters since.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Strategic Wealth Management's 13F filing for Q4 2021, filed 7 Feb 2022.